Opportunity
Alberta Purchasing #NOA 2024-0162
Award for Synthesis of saRNAs, mRNA, and LNP Formulations for Flu Constructs
Posted
August 28, 2024
Identifier
NOA 2024-0162
NAICS
325414, 541714
This award notice details a specialized research contract supporting mRNA vaccine production at the University of Alberta. - Government Buyer: - University of Alberta (Canada) - Project approved by the Canada Biomedical Research Fund (CBRF) - OEMs and Vendors: - Global Life Sciences Solutions Canada ULC, operating as Cytiva (formerly Precision Nanosystems) - Products/Services Requested: - Synthesis of self-amplifying RNAs (saRNAs) and messenger RNA (mRNA) - Manufacturing of lipid nanoparticle (LNP) formulations for eight flu constructs (seven saRNAs, one mRNA) - No specific part numbers or quantities provided - Unique or Notable Requirements: - Direct award under a trade agreement exception - Focus on advanced mRNA and LNP technologies for vaccine research - No additional requirements or NDA specified - Award Value: - $178,755 USD - Place of Performance: - University of Alberta, Edmonton, Alberta, Canada
Description
This notice of award from the University of Alberta pertains to a research project involving the synthesis of saRNAs and mRNA and the manufacturing of lipid nanoparticle (LNP) formulations for 8 flu constructs, including 7 saRNAs and 1 mRNA. The awarded contract supports mRNA vaccine production research and is a direct award under a specific trade agreement exception. The contract was awarded to Global Life Sciences Solutions Canada ULC dba Cytiva, a key collaborator approved by the Canada Biomedical Research Fund. The award amount is approximately $178,755 USD.